Highest-materiality recent filing
Zomedica Q2 revenue $9.5M (+37% YoY), net loss down 49% to $3.8M
Record Q2 revenue of $9.5M, up 37% YoY; net loss reduced 49% to $3.8M from $7.4M.
Zomedica Q1 revenue record $8.8M, up 35% YoY; net loss narrows to $4.5M
Record Q1 revenue $8.8M, up 35% from $6.5M in Q1 2025; 21st straight quarter of YoY growth.
Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)
Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.
Zomedica Q3 2025 revenue $8.1M (+16% YoY); net loss narrows to $6.1M
Revenue $8.1M, up 16% YoY; gross margin 67%; Diagnostics segment grew 51%.
Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%
Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.
Zomedica Q1 revenue $6.5M (+4% YoY), net loss $63.8M on $55.8M impairment
Revenue $6.5M (+4% YoY); gross margin 68% vs 66% in Q1 2024.
CFO Scott Jordan resigns; VP Finance Michael Zuehlke assumes interim role
Scott Jordan resigned as CFO effective April 25, 2025; receives $80,769 lump sum and 3 months COBRA reimbursement.
Zomedica delisted from NYSE American, to trade on OTCQB starting March 5 under ZOMDF
NYSE American suspended trading March 4, 2025 due to low share price under Section 1003(f)(v).
Zomedica appoints Scott Jordan as CFO effective Jan 1, 2025; base salary $350K plus options
Scott Jordan appointed Executive VP Finance and CFO, effective January 1, 2025.
Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%
Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.
Zomedica CFO Peter Donato resigns; VP Finance Zuehlke steps in as interim
CFO Peter Donato resigned effective Aug 15, 2024; enters 3-year consulting agreement for transition.
Zomedica reports record FY2023 revenue $25.2M (+33% YoY); net loss $34.5M; guides FY2024 $31-35M
Q4 2023 revenue $7.3M (+19% YoY); FY2023 revenue $25.2M (+33% YoY), driven by Diagnostics (+252%) and Therapeutic Devices (+28%).
Zomedica Q1 revenue up 14% to $6.3M, net loss widens to $9.2M; FY guidance reaffirmed
Q1 2024 revenue $6.3M (+14% YoY) driven by 86% growth in Diagnostics and 9% in Therapeutic Devices.
Q4 2023 revenue $7.3M (+19% YoY); full-year revenue $25.2M vs $18.9M in 2022.
Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split
Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).
Zomedica shareholders reject 80-for-1 reverse stock split at special meeting
Share Consolidation Proposal required two-thirds approval; received only 39.44% 'for' votes.
Zomedica Q3 revenue up 31% to record $6.3M; net loss narrows to $0.3M; NYSE listing deficiency
Revenue of $6.3M, up 31% YoY; gross margin 69%, up from 67% sequential.
Zomedica acquires Qorvo Biotechnologies, maker of TRUFORMA platform, for undisclosed sum
Purchase price not disclosed; acquisition includes QBT's manufacturing and R&D staff in Plymouth, MN.
Zomedica gets NYSE American deficiency notice for low share price (<$0.20 avg)
30-trading day average share price fell below $0.20, triggering Section 1003(f)(v) non-compliance.
Zomedica closes $18M acquisition of Structured Monitoring Products, maker of VetGuardian
Acquired 100% of SMP for $18M enterprise value; paid $12.66M in cash after debt conversion and adjustments.
Zomedica Q2 revenue up 43% to $6.0M; net loss flat at $5.3M; cash $142.4M
Revenue $6.0M vs $4.2M YoY (+43%); therapeutic segment $5.8M (+38%), diagnostic $0.2M (+100%).
Zomedica Q1 revenue up 45% to $5.5M; net loss widens to $6.4M
Revenue $5.5M (+45% YoY); gross margin 70%; net loss $6.4M ($0.007/share) vs $3.9M loss a year ago.
Zomedica exercises option to acquire Structured Monitoring Products for $18M enterprise value
Exercised option to buy SMP, maker of VetGuardian remote monitoring system, at $18M enterprise value.
Zomedica appoints Peter Donato as CFO effective March 16, 2023; Ann Marie Cotter resigns
Ann Marie Cotter resigned as CFO effective March 16, will remain through April 15 for transition.
Zomedica reports 2022 revenue of $18.9M, up 361% YoY; net loss narrows to $17.0M
Revenue $18.9M, up 361% from $4.1M in 2021; 72% gross margin.
Zomedica sees Q4 rev $6.0-6.2M (+46-51% YoY); FY rev up ~360%
Q4 2022 revenue expected $6.0-$6.2M, +46-51% vs Q4 2021, driven by PulseVet and Assisi.
Zomedica restructures TRUFORMA deal with Qorvo; takes control of development and manufacturing
ZomInc pays $4M up-front license fee and up to another $4M upon cartridge production line qualification.
Zomedica begins commercializing VetGuardian wireless vital signs monitor via distribution deal
Zomedica subsidiary entered distribution agreement with Structured Monitoring Products for VetGuardian remote monitor.
Zomedica Q3 revenue $4.78M, net loss $5.0M; cash $158.5M
Total revenue $4.78M (vs $0.02M Q3 2021); gross margin 75%.
Zomedica acquires Assisi Animal Health for $18M cash plus warrants
Acquired substantially all assets of Assisi Animal Health for $18.0M cash and a 10-year warrant for 22M common shares at $0.252 per share.
Zomedica closes acquisition of Revo Squared for $6M cash plus warrants, earn-outs up to $4M
Completed acquisition of Revo Squared on July 1, 2022 for $6M base cash, subject to working capital adjustments.
Zomedica announces new 12,400 sq ft global manufacturing & distribution center in Roswell, GA
New 12,400 sq ft facility to more than double capacity; construction completion expected August 2022.
Zomedica acquires Revo Squared veterinary imaging assets for $6M cash plus earn-out and warrants
Base purchase price $6M cash, subject to working capital adjustments; $500K held in escrow for 15 months.
Zomedica Q1 revenue $3.8M, up 38% pro forma; net loss $3.9M
Revenue $3.8M (74% gross margin) vs $14K in Q1 2021; up 38% over combined Zomedica+PulseVet $2.7M.
Zomedica files pro forma financials for Pulse Veterinary acquisition; $71.9M cash price
Preliminary purchase price of $71.9M funded from cash; pro forma cash after deal $197.7M.
Zomedica CCO Bruk Herbst departs; separation agreement with benefits for termination without cause
Bruk Herbst separated from Zomedica as Chief Commercial Officer effective Nov 19, 2021.
Until a Chief Financial Officer is hired to replace Mr. Jordan, Mr. Michael Zuehlke, Vice President of Finance and Corporate Controller of Zomedica Inc. will assume operational responsibility for accounting and finance matters.
Effective April 25, 2025, Scott Jordan resigned from employment as Chief Financial Officer of Zomedica Corp.
On March 16, 2023, Ann Marie Cotter resigned from employment as Chief Financial Officer of Zomedica Corp.
Also on March 16, 2023, Peter Donato was appointed as the Company’s Chief Financial Officer, effective immediately.
On August 23, 2022 the Board of Directors (the “Board”) of Zomedica Corp. (the “Company”) increased the size of our Board from six to seven members and appointed Dr. Pamela Nichols, DVM to fill the newly created vacancy on the Board.
On June 13, 2022, the Company appointed Karen DeHaan-Fullerton as the Company’s Chief Counsel and Corporate Secretary.
On June 13, 2022, Zomedica Corp. (the “Company”) appointed Anthony K. Blair as the Company’s Chief Operating Officer, effective immediately.
On November 19, 2021, Bruk Herbst was separated from employment as Chief Commercial Officer of Zomedica Corp. (the “Company”).
On November 1, 2021, Mr. Heaton will succeed Robert Cohen as the Chief Executive Officer of the Company
On October 1, 2021, the Board of Directors of Zomedica Corp. (the “Company”) appointed Larry Heaton as the Company’s President, effective immediately.
Mr. Cohen’s previously announced retirement as Chief Executive Officer will be effective.
On September 13, 2021, the Board appointed Sean Whelan as a member of the Board to fill the vacancy created by Mr. Wolfenberg’s resignation.
Max materiality 0.80 · Median 0.65 · Most common event earnings